Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Entecavir].

Enfermedades infecciosas y microbiologia clinica - 1 May 2008

Calleja José Luis, Peñas Beatriz

Abstract excerpt

Chronic hepatitis B continues to be a serious problem worldwide. Because a high viral load is associated with greater progression to cirrhosis and hepatocarcinoma in these patients, new drugs that achieve rapid, potent and lasting suppression of viral replication must be sought. Entecavir is a new, highly potent antiviral agent; phase II and III studies have demonstrated this drug to be superior to placebo and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Randomized Controlled Trials as Topic
Share to Organophosphonates
Share to Adenine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Guanine

Share to Hepatitis B e Antigens

Share to Lamivudine

Share to Liver Transplantation

Share to Multicenter Studies as Topic

Source

Identifiers

PMID: 19100230
DOI: 10.1016/s0213-005x(08)76518-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Entecavir].PMID 19100230Read ↗

Use of entecavir for the treatment of complex forms of hepatitis B.Semantic proximity Read ↗

[Management of antiviral-resistant chronic hepatitis B virus infection].Semantic proximity Read ↗

[Emergence of entecavir genotypic resistance in a nucleoside naive chronic hepatitis B patient who had been treated for nearly five years: a case report].Semantic proximity Read ↗

[Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].Semantic proximity Read ↗

[Resistance in hepatitis B virus].Semantic proximity Read ↗

Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience.Semantic proximity Read ↗

Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.Semantic proximity Read ↗

Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.Semantic proximity Read ↗

[Genotypic resistance to entecavir in chronic hepatitis B patients].Semantic proximity Read ↗

Antiviral resistance and hepatitis B therapy #Semantic proximity Read ↗

[Efficacy and predictors of the virologic response to entecavir therapy in nucleoside-naive patients with chronic hepatitis B].Semantic proximity Read ↗

The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.